key: cord-1022920-zsusanjq
authors: Weston, Stuart; Coleman, Christopher M.; Haupt, Robert; Logue, James; Matthews, Krystal; Li, Yize; Reyes, Hanako M.; Weiss, Susan R.; Frieman, Matthew B.
title: Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
date: 2020-10-14
journal: J Virol
DOI: 10.1128/jvi.01218-20
sha: cbcab3af4f2409c0e089ee53423ca3a2e87a7ac9
doc_id: 1022920
cord_uid: zsusanjq

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China at the end of 2019 and has rapidly caused a pandemic, with over 20 million recorded COVID-19 cases in August 2020 (https://covid19.who.int/). There are no FDA-approved antivirals or vaccines for any coronavirus, including SARS-CoV-2. Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA-approved drugs. Rapid development and human testing of potential antivirals is urgently needed. Numerous drugs are already approved for human use, and subsequently, there is a good understanding of their safety profiles and potential side effects, making them easier to fast-track to clinical studies in COVID-19 patients. Here, we present data on the antiviral activity of 20 FDA-approved drugs against SARS-CoV-2 that also inhibit SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). We found that 17 of these inhibit SARS-CoV-2 at non-cytotoxic concentrations. We directly followed up seven of these to demonstrate that all are capable of inhibiting infectious SARS-CoV-2 production. Moreover, we evaluated two of these, chloroquine and chlorpromazine, in vivo using a mouse-adapted SARS-CoV model and found that both drugs protect mice from clinical disease. IMPORTANCE There are no FDA-approved antivirals for any coronavirus, including SARS-CoV-2. Numerous drugs are already approved for human use that may have antiviral activity and therefore could potentially be rapidly repurposed as antivirals. Here, we present data assessing the antiviral activity of 20 FDA-approved drugs against SARS-CoV-2 that also inhibit SARS-CoV and MERS-CoV in vitro. We found that 17 of these inhibit SARS-CoV-2, suggesting that they may have pan-anti-coronaviral activity. We directly followed up seven of these and found that they all inhibit infectious-SARS-CoV-2 production. Moreover, we evaluated chloroquine and chlorpromazine in vivo using mouse-adapted SARS-CoV. We found that neither drug inhibited viral replication in the lungs, but both protected against clinical disease.

Screening FDA-approved compounds for anti-SARS-CoV-2 activity. Previously, we performed a large-scale drug screen on 290 FDA-approved compounds to investigate which may have antiviral activity against SARS-CoV and MERS-CoV (6) . With the emergence of SARS-CoV-2, we prioritized testing 20 of the 27 hits that were determined to inhibit both of the previously tested coronaviruses for antiviral activity against the novel virus. The list of tested compounds is shown in Table 1 . Our screening started at 50 M and used an 8-point, 1:2 dilution series with infections being performed at a multiplicity of infection (MOI) of either 0.01 or 0.004. CellTiter-Glo (CTG) assays were performed 3 days post-infection (dpi) to determine relative cell viability between drug and vehicle control treated cells. Uninfected samples were used to measure the cytotoxicity of drug alone. From the relative luminescence data of the CTG assay, percent inhibition (of cell death caused by viral infection) could be measured and plotted along with the percent cytotoxicity of drug alone. Figure 1 shows the plotted graphs from one representative of three independent screens at an MOI of 0.01. For drugs demonstrating a cell toxicity rate lower than 30%, we were able to calculate IC 50 s at both MOI from these graphs for 17 of the 20 drugs (summarized in Table 1 ).

Drug screen validation. In order to validate our screening process as a means to identify compounds with antiviral effect, we decided to follow up with a subset of drugs. Chloroquine (CQ) has become the source of much interest as a potential treatment for COVID-19 (12) ; as such, we further investigated hydroxychloroquine (HCQ) and CQ, as both were present in our screen (Table 1) . Vero E6 cells were plated and pretreated with drug for 2 h prior to infection with SARS-CoV-2 at an MOI of 0.1. Supernatant was collected 24 h post-infection (hpi) to determine titer of virus by TCID 50 (50% tissue culture infective dose) assay, and cells were collected in TRIzol to assess production of viral mRNA. Treatment with both drugs caused a significant reduction in viral mRNA levels, especially at higher concentrations, without drug-induced cytotoxicity ( Fig. 1 and Table 1 ). There was a significant decrease in relative expression levels of both RNA-dependent RNA polymerase (RdRp) and nucleoprotein (N) mRNA across the range of concentrations used ( Fig. 2A to D) . Along with causing a reduction in viral mRNA, treatment with both drugs caused a significant reduction in viral replication ( Fig.  2E and F). SARS-CoV-2 production was more sensitive to HCQ than CQ, with larger inhibition seen at the same concentration of treatment, which is in agreement with HCQ having a lower IC 50 in our cell viability assay (Table 1) . We also performed a time-of-addition assay with the highest concentration of HCQ to investigate whether SARS-CoV-2 entry was the point of inhibition of this compound (Fig. 2G) . Interestingly, while the addition of HCQ at 2 hpi did result in some reduction in inhibitory activity, there was not a complete loss, suggesting that HCQ treatment may impact other stages of the viral life cycle than just entry.

We previously used a ␤-lactamase-Vpr chimeric protein (Vpr-BlaM) pseudotype system to demonstrate that imatinib (a drug also seen to inhibit SARS-CoV-2 [ Table 1 and Fig. 1 ]) inhibits SARS-CoV and MERS-CoV spike-mediated entry (9) . We used this system to more directly investigate whether CQ could inhibit viral entry mediated by coronavirus spike, and we additionally included chlorpromazine (CPZ), as it is known to inhibit clathrin-mediated endocytosis (13) and was also part of our drug screening (Table 1 and Fig. 1 ). In this assay, when the pseudovirus fuses with a cellular membrane, BlaM is released into the cytoplasm of the infected cell. BlaM cleaves cytoplasmic loaded CCF2 to change its emission spectrum from 520 nm (green) to ϳ450 nm (blue), which can be quantified by flow cytometry. Cells were treated with CQ or CPZ for 1 h before infection with BlaM-containing SARS-CoV spike (SARS-S) pseudovirions (PV). Cells were then analyzed by flow cytometry to quantify the cleavage of CCF2. In mock-treated cells infected with SARS-S PV, there was a shift in the CCF2 emission spectrum, indicating that BlaM had been released to the cytosol and that spike-mediated fusion with cellular membranes had occurred. Upon treatment with CQ or CPZ, there was a Ͼ90% reduction in CCF2 cleavage caused by SARS-S PV (Fig. 2H) . These data demonstrate that both drugs inhibit SARS-CoV spike-mediated fusion with cellular membranes. These pseudotype assays suggest that the inhibition of coronavirus replication caused by CQ and CPZ is at the stage of entry into cells, but when these results are combined with those of the time-of-addition assays (Fig. 2G) , there is a suggestion that later stages may also be impacted. HCQ and CQ are used as antimalarial drugs and are in the class of aminoquinolines, which are hemozoin inhibitors. Interestingly, from our drug screening, three other hemozoin inhibitors were identified: amodiaquine dihydrochloride dihydrate, amodiaquine hydrochloride, and mefloquine. We therefore decided to directly test these drugs for antiviral activity against SARS-CoV-2. We directly tested CPZ against SARS-CoV-2, having seen that it could inhibit SARS-CoV S-mediated entry into cells (Fig. 2H) . We also included imatinib, since we had previously shown that it can inhibit entry of both SARS-CoV and MERS-CoV (9) and was a hit against SARS-CoV-2 ( Fig. 1 and Table  1 ). Again, Vero E6 cells were pretreated with drugs at various concentrations and infected with SARS-CoV-2 at an MOI of 0.1 for 24 h, after which supernatant samples were collected. As can be seen in Fig. 3 , at the highest concentrations of all drugs there was significant inhibition of SARS-CoV-2 infection. All five drugs showed high levels of inhibition at a non-cytotoxic concentration of 20 M (see Fig. 1 for toxicity data).

Overall, the data from Fig. 2 and 3 indicate that there are various FDA-approved drugs that have broad-spectrum anti-coronavirus activity in vitro and that our initial screening based on cytopathic effect is a good method to identify compounds with antiviral activity.

Our screening and subsequent initial follow-up were performed in Vero E6 cells, which are an African green monkey kidney epithelial cell line. We also wanted to determine whether the selected 7 drugs in our follow-up inhibited SARS-CoV-2 replication in a human cell line. For this, we used A549 lung adenocarcinoma cells that stably express human ACE2 (A549-hACE2), the SARS-CoV-2 receptor protein. As before, cells were pretreated with each compound for 2 h using a single dose point (50 M for HCQ and CQ and 20 M for the other 5) and then infected with SARS-CoV-2. We found in these cells that peak titer was achieved at 48 hpi; therefore, supernatant was collected at this time point and used to determine titers of released virus, and cells were collected in TRIzol for RNA expression analysis. All 7 of these drugs were capable of causing a significant reduction in replication of SARS-CoV-2 in A549 cells, in terms of both RNA production for both RdRp and N genes ( Fig. 4A and B) and infectious virus production (Fig. 4C) . These data show that these 7 FDA-approved drugs are able to inhibit in vitro replication of SARS-CoV-2 in human cells.

Chloroquine and chlorpromazine do not inhibit SARS-CoV (MA15) replication in mouse lungs but significantly reduce weight loss and clinical signs. CQ and CPZ treatment displayed significant inhibition of coronavirus replication in vitro, with our data suggesting that entry is inhibited. We therefore decided to investigate whether these drugs were efficacious in vivo using the SARS-CoV strain MA15 in BALB/c mice (11) . There is currently no well-established SARS-CoV-2 small animal model, and therefore, we used SARS-CoV MA15 as a surrogate. Since we think that CQ and CPZ impact

concentration (or 0.1% water as a vehicle control) for 2 h prior to infection with SARS-CoV-2 at an MOI of 0.1. Cells were collected in TRIzol 24 hpi. RNA was extracted from the TRIzol sample, and qRT-PCR was performed for viral RdRp (A and B) or N (C and D) mRNA using WHO primers. RNA levels were normalized with 18S RNA, and fold change for drug-treated cells relative to vehicle control was calculated (dotted lines indicate a fold change of 1, which is no change over control). Data are from 3 independent infections performed on triplicate wells; the fold change was calculated in each independent experiment, and the mean fold change is plotted, with error bars displaying standard deviations. Along with TRIzol samples for RNA, supernatant was collected from cells and used for TCID 50 assays to determine infectious-virus production following treatment with HCQ (E) or CQ (F). Data are from 3 independent infections performed on triplicate wells, with the TCID 50 per milliliter being averaged across all wells. entry and that both viruses use the same cellular receptor of ACE2 (14-17), we believe this to be a good model. The MA15 model displays ϳ15 to 20% weight loss by 4 dpi, occasionally resulting in death. We tested whether prophylactically administered CQ or CPZ could protect mice from severe MA15 infection. Mice were injected intraperitoneally with either water, 0.8 mg CQ, 1.6 mg CQ, 20 g CPZ, 100 g CPZ, or 200 g CPZ at day Ϫ1 of infection and then were dosed every day through the 4 days of infection. On day 0, mice were intranasally infected with 2.5 ϫ 10 3 PFU of MA15 virus or phosphatebuffered saline (PBS) as a control. Weight loss was measured as a correlate of disease, and mice were euthanized at 4 dpi for analysis.

PBS-inoculated mice showed no weight loss or clinical signs of disease when treated with either water, CQ, or CPZ over the experiment time course, indicating that drug treatment did not adversely affect morbidity (Fig. 5A) . Mice that were infected with MA15 and treated with water lost ϳ15% of their starting body weight over 4 days and had significant clinical signs of disease, including ruffled fur, labored breathing, and lethargy ( Fig. 5A and 6A ). Mice that were treated with 0.8 mg of CQ each day displayed weight loss similar to that seen with the water control through the first 3 days of infection; however, by 4 dpi, the weight loss was halted in the drug-treated mice (Fig.  5A) . Mice that were treated with 1.6 mg CQ per day showed markedly reduced weight loss compared to the water control (Fig. 5A) . Pathological analysis was also performed on hematoxylin-and-eosin (H&E)-stained sections. Mice infected with MA15 and treated with water displayed significant inflammation and denuding bronchiolitis, suggesting severe disease (Fig. 5B) . In contrast, the 0.8-mg-CQ group had moderate inflammation that was reduced compared to that in controls, and the 1.6-mg group had minimal lung (Fig. 5B) . Interestingly, even though CQ treatment appeared to protect against weight loss and inflammation in the lungs, the viral titer was equivalent between drug-treated and vehicle control mice (Fig. 5C ). Similar to the CQ results, CPZ treatment reduced weight loss in mice infected with MA15 at 100 g and 200 g, but the 20-g treatment group was equivalent to the vehicle control group (Fig. 6A) , and the H&E sections showed protection against inflammation and denuding bronchiolitis at the higher doses (Fig. 6B) . Again, as with CQ treatment, even though there were reduced signs of infection with CPZ treatment, there was no difference in MA15 titer in the mouse lungs (Fig. 6C) . Overall, these data indicate that even though CQ and CPZ treatment do not inhibit viral replication in the lungs, both can protect mice from signs of disease following SARS-CoV (MA15) infection.

The SARS-CoV-2 pandemic has demonstrated the desperate need for antiviral drugs. Since the emergence of SARS-CoV in 2002, research has uncovered many details of coronavirus biology and pathogenesis; however, there are currently no approved therapeutics against this emerging virus family. Whether they are used for treating SARS-CoV-2 in this current pandemic or fir the next unknown viral pathogen, we must attempt to develop and validate antiviral drugs that are ready to be used at the first signs of an outbreak. Many FDA-approved drugs have been found to have antiviral activity in addition to their approved use (for examples, see references [5] [6] [7] [8] , and since these are extensively used in humans for other conditions, they could be streamlined for rapid approval and repurposing as antivirals. In our previous work, 290 FDA approved drugs were screened for antiviral activity, and 27 were found to inhibit both SARS-CoV and MERS-CoV (6) . We prioritized testing these for antiviral activity against SARS-CoV-2, since they displayed broad anti-coronaviral activity. From multiple independent screens performed with two MOI, we found that 17 of our 20 tested priority compounds display significant antiviral activity at noncytotoxic concentrations. Many of the compounds have IC 50 s under 10 M, and these will be the source of follow-up testing on additional cell lines and in small animal models of SARS-CoV-2 and in combinatorial studies.

We further investigated seven of the hits to directly test if they inhibited SARS-CoV-2 replication. We performed follow-up experiments with HCQ, CQ, amodiaquine, and mefloquine, because chloroquine has garnered much interest as a potential treatment for COVID-19 (12) and the others are similarly used as antimalarial drugs (18) . In addition, we previously demonstrated that imatinib is an inhibitor of SARS-CoV, MERS-CoV, and infectious bronchitis virus entry into cells (9, 10), so we included it here, as its mechanism of coronavirus inhibition is understood. Finally, CPZ inhibits clathrin function in cells (13) , so it can disrupt infection by many viruses that require clathrinmediated endocytosis, and it was therefore also chosen for further analysis. Treatment of cells with all of these drugs showed inhibition of infectious viral particle production (measured by TCID 50 assay) at non-cytotoxic levels.

Having demonstrated that HCQ, CQ, and CPZ can inhibit cytopathic effect, mRNA synthesis, and infectious viral particle production of SARS-CoV-2, we used a previously published system of SARS-CoV pseudotype viruses carrying Vpr-BlaM to investigate whether CQ and CPZ inhibit coronavirus spike-mediated entry to better define mechanism of action. We previously used this system to define imatinib as an entry inhibitor of these viruses (9) and found similar results for CQ and CPZ, thus better defining their mechanism of antiviral activity.

Finally, we investigated the efficacy of CQ and CPZ with an in vivo model using SARS-CoV MA15. There is currently a lack of a well-established mouse model for SARS-CoV-2, so we used the mouse-adapted SARS-CoV (MA15) strain as a surrogate to assess the in vivo efficacy of these drugs against a closely related coronavirus. We are of the opinion that this is a good model, since both viruses use ACE2 as a receptor (14) (15) (16) (17) and therefore have similar cellular tropisms, which is important, since both of these compounds appear to inhibit viral entry. Prophylactic dosing in MA15 infection experiments demonstrated that, in contrast to the in vitro antiviral activity, CQ and CPZ did not inhibit viral replication in mouse lungs based on viral titers recovered at 4 dpi. However, both drugs resulted in reduced weight loss and improved clinical outcome, with the higher dose giving greater protection. Along with being an anti-malarial, CQ is used in humans for the treatment of systemic lupus erythematosus and rheumatoid arthritis because of its anti-inflammatory properties and effects on antigen presentation (19) (20) (21) . We speculate that these properties may have a role in the protection we observed in vivo, since much of the pathology from SARS-CoV is a consequence of immunopathology during infection (in mice [22] and in nonhuman primates [23] ; for a detailed review, see reference 24). Since CPZ treatment resulted in a similar phenotype, we speculate that its role as an inhibitor of clathrin-mediated endocytosis may have an impact on cells of the immune system. HCQ and CQ have been examined in patients with COVID-19, and we are of the opinion that these drugs may not be viable therapeutics alone, since they do not inhibit viral replication in mouse lungs. However, the anti-inflammatory properties of these drugs, or other similar drugs, could potentially have a benefit for treatment of SARS-CoV-2 in combination with more directly acting antivirals, such as remdesivir (25) (26) (27) . Chloroquine and hydroxychloroquine have become the source of much controversy for the treatment of COVID-19 and many studies suggest that they do not impact the course of disease (28) (29) (30) . However, there are various ongoing clinical studies; a search on www.clinicaltrials.gov for "COVID-19 and hydroxychloroquine" returned close to 250 results. Our data suggest that in mice, chloroquine may have some impact on course of disease, but not on viral replication, when administered prophylactically. The need for prophylactic administration may mean that this is not a viable option in humans, but further clinical study is required. The development of antiviral drugs for emerging coronaviruses is a global priority. In the midst of the COVID-19 pandemic, we must identify rapidly accessible therapeutics that are validated in both in vitro and in vivo models. FDA-approved drugs being assessed for repurposing and other experimental drugs in development must be properly validated in animal studies to best assess their potential utility in people. We present here a list of FDA-approved drugs that are effective in vitro against SARS-CoV-2 as well as being effective against SARS-CoV and MERS-CoV (6) . Moreover, we have demonstrated that two of these, CQ and CPZ, can protect mice from severe clinical disease from SARS-CoV. Future research will be aimed at testing these compounds in SARS-CoV-2 animal models to further assess their potential utility for human treatment.

Cell lines and virus. Vero E6 cells (ATCC CRL 1586) were cultured in Dulbecco's modified Eagle medium (DMEM; Quality Biological), supplemented with 10% (vol/vol) fetal bovine serum (Sigma), 1% (vol/vol) penicillin-streptomycin (Gemini Bio-products), and 1% (vol/vol) L-glutamine (2 mM final concentration; Gibco). A549-hACE2 cells were cultured in DMEM with 10% fetal bovine serum and 1% penicillin-streptomycin. Cells were maintained at 37°C and 5% CO 2 . Samples of SARS-CoV-2 were obtained from the CDC following isolation from a patient in Washington State (WA-1 strain; BEI number NR-52281). Stocks were prepared by infection of Vero E6 cells for 2 days when cytopathic effect (CPE) was starting to be visible. Media were collected and clarified by centrifugation prior to being aliquoted for storage at Ϫ80°C. The titer of the stock was determined by plaque assay using Vero E6 cells as described previously (31) . All work with infectious virus was performed in a biosafety level 3 laboratory and approved by our institutional biosafety committee. SARS-CoV stock was prepared as previously described (32) . SARS-CoV spike (S) pseudotype viruses were produced as previously described (9) .

Drug testing. All drug screens were performed with Vero E6 cells. Cells were plated in opaque 96-well plates 1 day prior to infection. Drug stocks were made in either dimethyl sulfoxide (DMSO), water, or methanol. Drugs were diluted from stock to 50 M and an 8-point 1:2 dilution series made. Cells were pretreated with drug for 2 h at 37°C and 5% CO 2 prior to infection at an MOI of 0.01 or 0.004. Vehicle controls were used on every plate, and all treatments were performed in triplicate for each screen. In addition to plates that were infected, parallel plates were left uninfected to monitor cytotoxicity of drug alone. Three independent screens with this setup were performed. Cells were incubated at 37°C and 5% CO 2 for 3 days before CellTiter-Glo (CTG) assays were performed as per the manufacturer's instructions (Promega). Luminescence was read using a Molecular Devices SpectraMax L plate reader. Fluphenazine dihydrochloride, benztropine mesylate, amodiaquine hydrochloride, amodiaquine dihydrochloride dihydrate, thiethylperazine maleate, mefloquine hydrochloride, triparanol, terconazole Vetranal, anisomycin, fluspirilene, clomipramine hydrochloride, hydroxychloroquine sulfate, promethazine hydrochloride, emetine dihydrochloride hydrate, and chloroquine phosphate were all purchased from Sigma. Chlorpromazine hydrochloride, toremifene citrate, tamoxifen citrate, gemcitabine hydrochloride, and imatinib mesylate were all purchased from Fisher Scientific.

Data analysis. Cytotoxicity data were normalized according to cell-only uninfected controls and CTG medium-only (blank) controls: {1 Ϫ [(drug Ϫ blank)/(cell only Ϫ blank)]} ϫ 100. Inhibition data were normalized according to cell-only data and the activity of the vehicle controls: [(drug Ϫ vehicle)/(cell only Ϫ vehicle)] ϫ 100.

Nonlinear regression analysis was performed on the normalized percent inhibition and cytotoxicity data, and IC 50 s and half-maximal cytotoxic concentrations (CC 50 s) were calculated from fitted curves (log[agonist] versus response Ϫ variable slope [four parameters]) (GraphPad Software, La Jolla, CA), as described previously (33) . Drug dilution points in a given run were excluded from IC 50 analysis if the average cytotoxicity was greater than 30% (arbitrary cutoff) across the 3 cytotoxicity replicates for that screen. IC 50 s or CC 50 s extrapolated outside the drug dilution range tested were reported as greater than 50 M or less than 0.39 M. Selectivity indexes (SI) were also calculated by dividing the CC 50 by the IC 50 .

China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China

Screening of FDA-approved drugs for treatment of emerging pathogens

Drug repurposing: progress, challenges and recommendations

Drug repurposing for viral infectious diseases: how far are we?

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

Evaluation of Ebola virus inhibitors for drug repurposing

Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen

Abl kinase inhibitors are potent inhibitors of SARS-CoV and MERS-CoV fusion

Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice

Review: hydroxychloroquine and chloroquine for treatment of SARS

Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus

SARS-CoV-2 cell entry depends on ACE2 and TM-PRSS2 and is blocked by a clinically proven protease inhibitor

Effectiveness of antimalarial drugs

Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells

Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection

Exacerbated innate host response to SARS-CoV in aged non-human primates

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19

Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19

Observational study of hydroxychloroquine in hospitalized patients with COVID-19

Growth and quantification of MERS-CoV infection

Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease

In vitro and in vivo activity of amiodarone against Ebola virus

Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1ϩ endolysosomes is a rate-defining step

We kindly thank Emergent BioSolutions for financial support to perform these experiments. S. We declare no competing interests.